BeyondSpring (BYSI) Stock Overview
A clinical stage biopharmaceutical company, focuses on the development of cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BYSI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
BeyondSpring Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.76 |
| 52 Week High | US$3.44 |
| 52 Week Low | US$0.98 |
| Beta | 0.26 |
| 1 Month Change | -5.88% |
| 3 Month Change | 3.53% |
| 1 Year Change | -7.12% |
| 3 Year Change | 18.92% |
| 5 Year Change | -82.38% |
| Change since IPO | -89.52% |
Recent News & Updates
Recent updates
Here's Why BeyondSpring (NASDAQ:BYSI) Must Use Its Cash Wisely
Jun 10
Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation
Jun 21BeyondSpring, Beyond Salvage
Feb 03Circling Back On BeyondSpring
Nov 16Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns
Sep 18BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk
Sep 07BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
Aug 01How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?
Dec 22
Shareholder Returns
| BYSI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.4% | 0.5% | -1.5% |
| 1Y | -7.1% | -8.8% | 14.4% |
Return vs Industry: BYSI exceeded the US Biotechs industry which returned -8.8% over the past year.
Return vs Market: BYSI underperformed the US Market which returned 14.4% over the past year.
Price Volatility
| BYSI volatility | |
|---|---|
| BYSI Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BYSI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BYSI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 40 | Lan Huang | beyondspringpharma.com |
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company’s lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia.
BeyondSpring Inc. Fundamentals Summary
| BYSI fundamental statistics | |
|---|---|
| Market cap | US$69.37m |
| Earnings (TTM) | -US$8.18m |
| Revenue (TTM) | n/a |
Is BYSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BYSI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$8.18m |
| Earnings | -US$8.18m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.20 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BYSI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/21 23:58 |
| End of Day Share Price | 2025/08/21 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BeyondSpring Inc. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Jason Matthew Gerberry | BofA Global Research |
| Joshua Schimmer | Evercore ISI |